Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype

Cardiovascular Diabetology

Original Investigation

Juan Sánchez-Hernández¹  José Luis Sánchez-Quesada²  Jordi Ordoñez-Llanos³  David Santos⁴  Alberto De Leiva⁵  Antonio Pérez⁶  Irene Vinagre⁷ 

[1] CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain;Cardiovascular Biochemistry, Biomedical Research Institute IIB Sant Pau, Barcelona, Spain;Cardiovascular Biochemistry, Biomedical Research Institute IIB Sant Pau, Barcelona, Spain;Biochemistry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona, Barcelona, Spain;Cardiovascular Biochemistry, Biomedical Research Institute IIB Sant Pau, Barcelona, Spain;CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain;Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, C/ Mas Casanovas 90, 08025, Barcelona, Spain;CIBER of Biomedicine, Biotechnology and Nanomedicine (CIBERBBN), Barcelona, Spain;Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, C/ Mas Casanovas 90, 08025, Barcelona, Spain;CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Barcelona, Spain;Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, C/ Mas Casanovas 90, 08025, Barcelona, Spain;Universitat Autònoma de Barcelona, Barcelona, Spain;

关键词: Inflammatory biomarkers;    C-reactive protein;    Adiponectin;    Monocyte chemotactic protein-1;    Transforming growth factor-β;    Tumor growth factor β;    Type 2 diabetes;    LDL phenotype;    Atherogenic dyslipidemia;   

DOI  :  10.1186/1475-2840-13-34

 received in 2014-01-09, accepted in 2014-02-03,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundType 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk partly related to an increase in inflammatory parameters. The aim of this study was to determine the association of inflammatory biomarkers with low-density lipoprotein (LDL) subfraction phenotype and glycemic control in subjects with T2D and poor glycemic control.MethodsA cross-sectional study was performed comparing 122 subjects with T2D (59 ± 11 years old, body mass index 30.2 ± 5.6 kg/m2) with 54 control subjects. Patients with T2D were classified according to their LDL subfraction phenotype and inflammatory biomarkers (C-reactive protein, Interleukin-6, Interleukin-8, Transforming growth factor β1, Monocyte chemotactic protein 1, Leptin, Adiponectin) were evaluated according to the degree of glycemic control, LDL phenotype and other clinical characteristics. Forty-two subjects with T2D were studied before and after 3 months of improving glycemic control by different strategies.ResultsPatients with T2D had higher C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP1) levels and lower adiponectin concentration, compared to controls. T2D subjects with body mass index ≥ 30 kg/m2 had higher CRP levels (5.2 ± 4.8 mg/l vs 3.7 ± 4.3 mg/l; p < 0.05). The presence of LDL phenotype B was related to higher levels of transforming growth factor-β1 (TGF-β1) (53.92 ± 52.82 ng/l vs 31.35 ± 33.74 ng/l; p < 0.05) and lower levels of adiponectin (3663 ± 3044 ng/l vs 2723 ± 1776 ng/l; p < 0.05). The reduction of HbA1c from 9.5 ± 1.8% at baseline to 7.4 ± 0.8% was associated with a significant reduction of TGF-β1 (41.86 ± 32.84 ng/l vs 26.64 ± 26.91 ng/l; p = 0.02).ConclusionsSubjects with T2D, especially those with LDL phenotype B and obesity, have higher levels of inflammatory biomarkers. Improvement of glycemic control reduces TGF-β1 levels, which may contribute partly to its renoprotective role.

【 授权许可】

CC BY   
© Vinagre et al.; licensee BioMed Central Ltd. 2014